Mara Epstein to Comorbidity
This is a "connection" page, showing publications Mara Epstein has written about Comorbidity.
Connection Strength
0.399
-
Casta?eda-Avila MA, Lapane KL, Person SD, Zhou Y, Gurwitz J, Mazor KM, Epstein MM. Multi-trajectory models of serum biomarkers among patients with monoclonal gammopathy of undetermined significance. Hematol Oncol. 2022 Aug; 40(3):409-416.
Score: 0.154
-
Castaneda-Avila MA, Ulbricht CM, Epstein MM. Risk factors for monoclonal gammopathy of undetermined significance: a systematic review. Ann Hematol. 2021 Apr; 100(4):855-863.
Score: 0.142
-
Fillmore NR, DuMontier C, Yildirim C, La J, Epstein MM, Cheng D, Cirstea D, Yellapragada S, Abel GA, Gaziano JM, Do N, Brophy M, Kim DH, Munshi NC, Driver JA. Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma. J Natl Cancer Inst. 2021 08 02; 113(8):1084-1093.
Score: 0.037
-
Frendl DM, FitzGerald G, Epstein MM, Allison JJ, Sokoloff MH, Ware JE. Predicting the 10-year risk of death from other causes in men with localized prostate cancer using patient-reported factors: Development of a tool. PLoS One. 2020; 15(12):e0240039.
Score: 0.035
-
Clarke CL, Kushi LH, Chubak J, Pawloski PA, Bulkley JE, Epstein MM, Burnett-Hartman AN, Powell B, Pearce CL, Spencer Feigelson H. Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients. Cancer Epidemiol Biomarkers Prev. 2019 05; 28(5):996-999.
Score: 0.031